PE-22-28: The TREK-1 Blocker Studied as a Fast Antidepressant

PE-22-28 is a synthetic analog of spadin, a naturally occurring peptide fragment, developed as a blocker of the TREK-1 potassium channel. It emerged from a specific and elegant line of neuroscience research into rapid-onset antidepressant mechanisms, and its evidence base is entirely preclinical.

This guide situates PE-22-28 within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.

How TREK-1 became a target

TREK-1 is a two-pore-domain potassium channel expressed in brain regions involved in mood regulation, including areas rich in serotonergic neurons. Potassium channels of this type set the resting membrane potential and thereby influence how readily a neuron fires.

The finding that made TREK-1 interesting came from genetics. Mice lacking the TREK-1 gene display a depression-resistant phenotype — they behave in standard behavioral assays as though they are already receiving antidepressant treatment, and show altered serotonergic function consistent with that.

That is a strong form of target validation: removing the channel produces the effect a drug is trying to achieve. It suggested that pharmacologically blocking TREK-1 might produce antidepressant effects.

The clinical motivation is real. Conventional antidepressants typically require several weeks to produce benefit, a delay that is dangerous in severely depressed patients. A mechanism producing faster onset would be genuinely valuable, which is also why ketamine's rapid effects generated so much interest.

From spadin to PE-22-28

Spadin is a peptide fragment generated during the processing of the sortilin precursor protein, and it was found to act as a natural TREK-1 blocker.

In rodent studies, spadin produced antidepressant-like effects with a notably faster onset than conventional agents, along with evidence of increased hippocampal neurogenesis — a process associated with antidepressant action.

PE-22-28 is a shortened analog developed to improve stability and pharmacologic properties while retaining TREK-1 blocking activity. It represents the optimization step between an interesting natural fragment and a potential drug.

Where the evidence stops

The reported effects come from rodent behavioral models — forced swim, tail suspension and similar assays — alongside neurochemical and neurogenesis measures.

These models require careful interpretation. They have identified compounds that became effective antidepressants, and they have also produced a long list of compounds that showed activity in rodents and failed entirely in human trials. Depression is not a condition that animal behavior can model well, since its core features are subjective states an animal cannot report.

There are no human clinical trials of PE-22-28. Its safety, dosing, pharmacokinetics and efficacy in people are entirely uncharacterized. It is at an earlier stage than most compounds discussed in this formulary.

Status

PE-22-28 is not FDA-approved, is not an established compounding substance, and is not available as a legitimate therapy. Material sold online is unregulated research chemical.

This warrants a specific caution. Depression is a serious condition with meaningful mortality, and patients who are unwell and frustrated with treatment delays are exactly the group most likely to try an unproven compound. Someone substituting an unregulated research chemical for evidence-based treatment is taking a real risk.

Patients seeking faster-acting options should know that approved rapid-onset treatments do exist and are accessible through psychiatric care. Our peptide formulary tracks status across the category.